Insider Sale: COO Heather Prichard Divests All Shares in Humacyte Inc (HUMA)

Written by Emily J. Thompson, Senior Investment Analyst

HUMA-3.11%

HUMAW+3.99%

Source: Yahoo Finance

Updated: Jun 03 2024

0mins

Source: Yahoo Finance

Heather Prichard Insider Transaction: Heather Prichard, COO of Humacyte Inc, sold 191,511 shares, now owning none, indicating a significant change in investment position.
Humacyte Inc Focus: The biotechnology company focuses on developing human acellular vessels for various therapeutic areas to enhance treatment outcomes for patients with vascular and other diseases.
Insider Selling Trend: Over the past year, there have been 11 insider sells and only 3 insider buys at Humacyte Inc, reflecting a trend of selling activities among insiders.
Company Valuation Metrics: Humacyte Inc's market cap is $877.65 million, with key valuation metrics like GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow being important indicators for investors.
GuruFocus Article Insights: The article highlights the insider transaction trends at Humacyte Inc, emphasizing the prevalence of selling activities over buying, which could be of interest to potential investors and market analysts.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy HUMA?" and start using high-conviction signals backed by rigorous historical data.

Sign up today to access powerful investing tools and make smarter, data-driven decisions.

HUMA

$0.9977+Infinity%1D

Analyst Views on HUMA

Wall Street analysts forecast HUMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HUMA is 5.88 USD with a low forecast of 3.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Analyst Rating

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.030

Low

3.00

Averages

5.88

High

11.00

Current: 1.030

Low

3.00

Averages

5.88

High

11.00

Benchmark

Buy

maintain

$11 -> $10

2026-01-21

Reason

Benchmark

Price Target

$11 -> $10

AI Analysis

2026-01-21

maintain

Buy

Reason

Benchmark lowered the firm's price target on Humacyte to $10 from $11 and keeps a Buy rating on the shares after updating the firm's model for some recent financing activity, noting that its new price target is based on a sum-of-the-parts analysis.

Benchmark

Bruce Jackson

Buy

downgrade

$14 -> $11

2025-11-13

Reason

Benchmark

Bruce Jackson

Price Target

$14 -> $11

2025-11-13

downgrade

Buy

Reason

Benchmark analyst Bruce Jackson lowered the firm's price target on Humacyte to $11 from $14 and keeps a Buy rating on the shares post the Q3 report. The firm says the Symvess Acellular Tissue Engineered Vessel launch continued to gain new accounts during the quarter. It cites Humacyte's new shares for the target drop but believes the company's customer base continues to build.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HUMA

Unlock Now

About HUMA

Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for HUMA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy HUMA?

Get Started Free